Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare Professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

This website is intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk

About-Lynparza-hero-image.jpg

 

About LYNPARZA

What is the hypothetical mode of action for LYNPARZA combination therapy?

PARP and AR are important for DNA repair in prostate cancer. The interaction between PARP- and AR-signalling may explain the combined effect of LYNPARZA and abiraterone.1


In pre-clinical studies, inhibition of PARP and AR by LYNPARZA and abiraterone, respectively, results in increased DNA damage and anti-prostate cancer efficacy compared with controls.2–4

Interaction between PARP- and AR-signalling may explain the combined effect of LYNPARZA + abiraterone observed in preclinical models2,5,6

Lynparza-mechanism-of-action.svg

The mechanism for the pharmacological rationale for the efficacy of LYNPARZA in combination with abiraterone in mCRPC is hypothetical

Extrapolation of pre-clinical experimental evidence to clinical efficacy of the combination in patients cannot be made. The role of the addition of prednisone or prednisolone corticosteroid treatment to the pharmacological and genetic effects of the combination is unknown.2,5–7

Why combine LYNPARZA with abiraterone?

LYNPARZA cannot be combined with strong CYP3A4 inducers, such as enzalutamide, due to expected reduced exposure and hence reduced efficacy of LYNPARZA.8–10

 

Pancreas-icon.png

Hepatic cytochrome P450 enzymes
CYP3A4 and CYP3A5 are
predominantly responsible for the
metabolic clearance of LYNPARZA*8

 

*Hypothesis based on experimental models

Gear-Icon.png

Strong CYP3A4 inducers could
reduce plasma levels of LYNPARZA, potentially affecting efficacy
(e.g., co-administration of a strong CYP inducer, such as rifampicin, decreases the exposure to LYNPARZA)8

 

Line-graph-icon.png

Enzalutamide is a strong CYP3A4 inducer and therefore expected to reduce exposure of LYNPARZA and hence cannot be co-administered with LYNPARZA8–10

 

 

Common side effects of LYNPARZA combination therapy can be effectively managed in most patients11–19

LYNPARZA is the first PARP inhibitor recommended by NICE and accepted by the SMC in mCRPC, available as both monotherapy and in combination with abiraterone and prednisone or prednisolone21-24

NICE recommended and SMC accepted as combination therapy for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated21,24
 

 

NICE recommended and SMC accepted as monotherapy for treating hormone-relapsed mCRPC with BRCA1/2-mutations that has progressed after NHA (such as abiraterone or enzalutamide) in adults22,23


Please consult the SmPC for further information to minimise the risks associated with the use of the medicine before making any prescribing decisions.

LYNPARZA tablets are indicated as monotherapy for the treatment of adult patients with mCRPC and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy, including an NHA.11

 

LYNPARZA tablets are indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated.11

Want to learn more about LYNPARZA?

CONTACT US

AML=acute myeloid leukemia; AE=adverse event; AR=androgen receptor; CBC=complete blood count; CYP=cytochrome P450; HCP=healthcare professional; HRR=homologous recombination repair; HRRm=HRR mutation; MDS=myelodysplastic syndromes; mCRPC=metastatic castration-resistant prostate cancer; NHA=new hormonal agent; NICE=National Institute for Health and Care Excellence; PARP=poly (ADP-ribose) polymerase; PARPi=PARP inhibitor; SMC=Scottish Medicines Consortium; VTE=venous thromboembolic events.

 

  1. Chaudhuri AR & Nussenzweig A. Nat Rev Mol Cell Biol. 2017;18:610–621.
  2. Schiewer MJ, et al. Cancer Discov. 2012;2:1134–1149.
  3. Polkinghorn WR, et al. Cancer Discov. 2013;3:1245–1253.
  4. Pommier Y, et al. Sci Transl Med. 2016;8:362ps17.
  5. Goodwin JF, et al. Cancer Discov. 2013;3:1254–1271.
  6. Asim M, et al. Nat Commun. 2017;8:374.
  7. Li L, et al. Sci Signal. 2017;10:eaam7479.
  8. Dirix L, et al. Clin Ther. 2016;38:2286–2299.
  9. Gibbons JA, et al. Clin Pharmacokinet. 2015;54:1057–1069.
  10. Xtandi® (enzalutamide) 40 mg film coated tablets. Summary of Product Characteristics. December 2022. Available at: https://www.medicines.org.uk/emc/product/10318/smpc Accessed January 2026.
  11. LYNPARZA (olaparib). Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/9204/smpc Accessed January 2026.
  12. PROpel Protocol v1.0.
  13. American Cancer Society. Low Red Blood Cell Counts (Anaemia). Available at: https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/low-blood-counts/anemia.html. Accessed January 2026.
  14. American Society of Haematology. Anaemia. Available at: https://www.hematology.org/education/patients/anemia. Accessed January 2026.
  15. American Cancer Society. Managing Nausea and Vomiting at Home. Available at: https://www.cancer.org/treatment/treatments-and-side-effects/physical-side-effects/eating-problems/nausea-and-vomiting/managing.html. Accessed January 2026.
  16. Roubaud G, et al. Eur J Cancer 2022;170:73–84.
  17. Cancer Research UK. Fatigue and cancer drugs. Available at: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/cancer-drugs/side-effects/fatigue. Accessed January 2026.
  18. Cancer Research UK. Managing and treating cancer fatigue. Available at: https://www.cancerresearchuk.org/about-cancer/coping/physically/fatigue/managing-treating-cancer-fatigue. Accessed January 2026.
  19. Mayo Clinic. Cancer fatigue: Why it occurs and how to cope. Available at: https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-fatigue/art-20047709. Accessed January 2026.
  20. LaFargue CJ, et al. Lancet Oncol. 2019;20:e15–28.
  21. Olaparib with abiraterone for untreated hormone relapsed metastatic prostate cancer. NICE TA951. February 2024. Available at: https://www.nice.org.uk/guidance/ta951/resources/olaparib-with-abiraterone-for-untreated-hormonerelapsed-metastatic-prostate-cancer-pdf-82615723963333. Accessed January 2026.
  22. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer. May 2023. Available at: https://www.nice.org.uk/guidance/ta887/resources/olaparib-for-previously-treated-brca-mutationpositive-hormonerelapsed-metastatic-prostate-cancer-pdf-82613738657221. Accessed January 2026.
  23. Scottish Medicines Consortium. Olaparib (Lynparza). October 2021. Available at: https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-full-smc2366/. Accessed January 2026.
  24. Scottish Medicines Consortium. Olaparib (Lynparza) March 2024. Available at: https://www.scottishmedicines.org.uk/medicines-advice/olaparib-lynparza-mcrpc-full-smc2617/. Accessed January 2026.

 

GB-73793 | DOP: February 2026

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

Welcome to this UK AstraZeneca produced and funded website

This website is intended for UK Healthcare Professionals only.

 

The website contains both promotional and non-promotional content.

 

If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk

 

For any other UK residents please visit astrazeneca.co.uk

These Lynparza website pages were funded and produced by AstraZeneca UK and MSD UK.

 

This website is intended for UK Healthcare Professionals only.


The website contains both promotional and non-promotional content.


If you are a patient or a carer of a patient prescribed an AstraZeneca product, please visit myazmed.co.uk


For any other UK residents please visit astrazeneca.co.uk

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

GB-74216| DOP : February 2026